Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic pathways, will participate in the Canaccord Genuity 45th Annual Growth Conference.
The company's management will engage in a fireside chat on August 13, 2025, at 2 p.m. EDT in Boston, MA. Investors can access the webcast through Sagimet's website, with a replay available for 90 days after the event.
Sagimet Biosciences (Nasdaq: SGMT), una società biofarmaceutica in fase clinica specializzata nello sviluppo di nuovi trattamenti per vie metaboliche e fibrotiche, parteciperà alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity.
Il management dell'azienda prenderà parte a una conversazione informale il 13 agosto 2025 alle 14:00 EDT a Boston, MA. Gli investitori potranno seguire la diretta streaming tramite il sito web di Sagimet, con una replica disponibile per 90 giorni dopo l'evento.
Sagimet Biosciences (Nasdaq: SGMT), una empresa biofarmacéutica en etapa clínica enfocada en desarrollar terapias novedosas para vías metabólicas y fibróticas, participará en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity.
La dirección de la compañía participará en una charla informal el 13 de agosto de 2025 a las 2 p.m. EDT en Boston, MA. Los inversores podrán acceder a la transmisión en vivo a través del sitio web de Sagimet, con una repetición disponible durante 90 días posteriores al evento.
Sagimet Biosciences (나스닥: SGMT)는 대사 및 섬유화 경로를 위한 혁신적인 치료제를 개발하는 임상 단계 바이오제약 회사로, Canaccord Genuity 제45회 연례 성장 컨퍼런스에 참여할 예정입니다.
회사의 경영진은 2025년 8월 13일 오후 2시 EDT 보스턴, 매사추세츠에서 진행되는 대담에 참여합니다. 투자자들은 Sagimet 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 행사 후 90일 동안 다시보기가 가능합니다.
Sagimet Biosciences (Nasdaq : SGMT), une société biopharmaceutique en phase clinique spécialisée dans le développement de nouvelles thérapies pour les voies métaboliques et fibrosantes, participera à la 45e conférence annuelle sur la croissance de Canaccord Genuity.
La direction de l'entreprise participera à une discussion informelle le 13 août 2025 à 14h00 EDT à Boston, MA. Les investisseurs pourront accéder à la diffusion en direct via le site web de Sagimet, avec un replay disponible pendant 90 jours après l'événement.
Sagimet Biosciences (Nasdaq: SGMT), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf neuartige Therapien für metabolische und fibrotische Wege spezialisiert hat, wird an der 45. jährlichen Wachstumskonferenz von Canaccord Genuity teilnehmen.
Das Management des Unternehmens wird am 13. August 2025 um 14:00 Uhr EDT in Boston, MA, an einem Gespräch im kleineren Rahmen teilnehmen. Investoren können den Webcast über die Website von Sagimet verfolgen, eine Aufzeichnung steht für 90 Tage nach der Veranstaltung zur Verfügung.
- None.
- None.
SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 2 p.m. EDT in Boston, MA.
A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the US. For additional information about Sagimet, please visit www.sagimet.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Advisors
mfitzhugh@lifescicomms.com
FAQ
When is Sagimet Biosciences (SGMT) presenting at the Canaccord Genuity Conference?
How can investors access Sagimet Biosciences' (SGMT) Canaccord conference presentation?
What type of company is Sagimet Biosciences (SGMT)?
Where will the Canaccord Genuity Conference featuring Sagimet (SGMT) take place?
